PF 07799933
Alternative Names: ARRY-440; PF-07799933Latest Information Update: 25 Jun 2024
At a glance
- Originator Pfizer
- Class Antineoplastics; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 05 Apr 2024 Efficacy and adverse events data from phase-I trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 Pharmacodynamics data from preclinical trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 30 Nov 2022 Phase-I clinical trials in Solid tumours (Combination therapy, In adolescents, In adults, In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT05538130)